GU Onc Research Fellow @DanaFarber
Boston, MA
Joined April 2018
- Tweets148
- Following318
- Followers294
- Likes1K
Andrew Schmidt retweeted
Touring @SAiGENCI Level 9 facilities at AHMS Building with Director Designate, @ChrisSweens1
Andrew Schmidt retweeted
"Very favorable" risk group of mRCC was presented @ASCOGU21 by @dr_aschmidt
We externally validated the novel IMDC risk model in "Turkish Oncology Group Kidney Cancer Consortium" database
@DrYukselUrun @DrChoueiri @DrDanielHeng @OncoAlert
👇
clinical-genitourinary-cance…
Andrew Schmidt retweeted
Great summary of TKI adjuvant trials in RCC by @apolo_andrea Only STRAC showed a significant DFS benefit. Despite FDA approval not used widely, with toxicity issues and lack of OS
1/ Excited to share our work @COVID19nCCC on Breakthrough COVID-19 in Patients with Cancer @Annals_Oncology
Team effort with @Chrislabaki1 @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri ms.spr.ly/6018ZTfLa
1/Excited to share our work on COVID-19 breakthrough infections in patients w/cancer in @Annals_Oncology. Efforts led by co-1st authors @dr_aschmidt, @Chrislabaki1, C-Y. Hsu, @ZiadBakouny and co-seniors: @jeremywarner #YuShyr & @farmakiotis @COVID19nCCC
annalsofoncology.org/article…
Andrew Schmidt retweeted
1/ Thrilled to see our work on #COVID19 vaccination in pts with cancer from #CCC19 published.
W/ co-1st authors @dr_aschmidt @Chrislabaki1 C-Y Hsu! @Annals_Oncology @COVID19nCCC
The crux of it is that even w/ vaccination, some pts w/ cancer (heme ++) remain at high risk – at Lebanon
1/Excited to share our work on COVID-19 breakthrough infections in patients w/cancer in @Annals_Oncology. Efforts led by co-1st authors @dr_aschmidt, @Chrislabaki1, C-Y. Hsu, @ZiadBakouny and co-seniors: @jeremywarner #YuShyr & @farmakiotis @COVID19nCCC
annalsofoncology.org/article…
Andrew Schmidt retweeted
1/Excited to share our work on COVID-19 breakthrough infections in patients w/cancer in @Annals_Oncology. Efforts led by co-1st authors @dr_aschmidt, @Chrislabaki1, C-Y. Hsu, @ZiadBakouny and co-seniors: @jeremywarner #YuShyr & @farmakiotis @COVID19nCCC
annalsofoncology.org/article…
Andrew Schmidt retweeted
HIF-2α inhibition shows ‘encouraging results’ in kidney cancer trial. Study led by Dana-Farber’s Toni Choueiri, MD (@DrChoueiri), and published in @NatureMedicine looks at belzutifan in patients with metastatic renal cell carcinoma: ms.spr.ly/6012Vg5Sn cc @DanaFarber_GU
Recent IO trials have not progressed the field much in prostate cancer outside of MSI. Thank you @xiaoweimd @DanaFarber_GU summarising upcoming IO trials - buff.ly/3r44vvi
Fantastic summary from @ChrisSweens1 summarising mHSPC data for Docetaxel at the 20th Biennial Course in Urologic Oncology. Volume and time to mets refine benefit @Chrislabaki1 @ZiadBakouny
Andrew Schmidt retweeted
Latest PCOR-Vic🇦🇺registry data on docetaxel use in mHS #ProstateCancer. From 2014-18, 25% received docetaxel with age + Rx in private hosp. A/W sig.⬆︎chemo use. In 2018, 70% of <70yo Rx with docetaxel. RW impact of CHAARTED & STAMPEDE! bit.ly/3rRRwwG
Andrew Schmidt retweeted
#COVID19 #vaccines immune effect on cancer patients. @DanaFarber is looking for patients with GU/Breast cancer who plan to get the vaccine to participate in our new study: VERIFY-C, to determine immune responses. Please reach out to [email protected] @stolaney1 @nlinmd
SBRT is a useful modality in mRCC. Who is using it? Find out - Temporal trends and predictors in the use of SBRT for mRCC in the US dx.doi.org/10.1002/onco.1373…
@DrChoueiri @DrRanaMcKay @qdtrinh @DanaFarber_GU M.Paciotti MD, P.Ravi MD
7/ From ASCO GU 21 - look at field expert @_ShankarSiva report on SBRT + IO in oligometastatic disease
meetinglibrary.asco.org/reco…
@DrBenTran @AzadOncology @declangmurphy
Thank you to the team at @DanaFarber_GU, our co-authors and our mentors @DrChoueiri @qdtrinh for making this work possible.